Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

355 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program.
O'Connor CM, Miller AB, Blair JE, Konstam MA, Wedge P, Bahit MC, Carson P, Haass M, Hauptman PJ, Metra M, Oren RM, Patten R, Piña I, Roth S, Sackner-Bernstein JD, Traver B, Cook T, Gheorghiade M; Efficacy of Vasopressin Antagonism in heart Failure Outcome Study with Tolvaptan (EVEREST) investigators. O'Connor CM, et al. Among authors: konstam ma. Am Heart J. 2010 May;159(5):841-849.e1. doi: 10.1016/j.ahj.2010.02.023. Am Heart J. 2010. PMID: 20435194 Clinical Trial.
The impact of chronic obstructive pulmonary disease in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST Trial.
Mentz RJ, Schmidt PH, Kwasny MJ, Ambrosy AP, O'Connor CM, Konstam MA, Zannad F, Maggioni AP, Swedberg K, Gheorghiade M. Mentz RJ, et al. Among authors: konstam ma. J Card Fail. 2012 Jul;18(7):515-23. doi: 10.1016/j.cardfail.2012.04.010. Epub 2012 Jun 4. J Card Fail. 2012. PMID: 22748484 Clinical Trial.
Influence of documented history of coronary artery disease on outcomes in patients admitted for worsening heart failure with reduced ejection fraction in the EVEREST trial.
Mentz RJ, Allen BD, Kwasny MJ, Konstam MA, Udelson JE, Ambrosy AP, Fought AJ, Vaduganathan M, O'Connor CM, Zannad F, Maggioni AP, Swedberg K, Bonow RO, Gheorghiade M. Mentz RJ, et al. Among authors: konstam ma. Eur J Heart Fail. 2013 Jan;15(1):61-8. doi: 10.1093/eurjhf/hfs139. Epub 2012 Sep 11. Eur J Heart Fail. 2013. PMID: 22968743 Free PMC article. Clinical Trial.
Atrial fibrillation or flutter on initial electrocardiogram is associated with worse outcomes in patients admitted for worsening heart failure with reduced ejection fraction: findings from the EVEREST Trial.
Mentz RJ, Chung MJ, Gheorghiade M, Pang PS, Kwasny MJ, Ambrosy AP, Vaduganathan M, O'Connor CM, Swedberg K, Zannad F, Konstam MA, Maggioni AP. Mentz RJ, et al. Among authors: konstam ma. Am Heart J. 2012 Dec;164(6):884-92.e2. doi: 10.1016/j.ahj.2012.09.011. Epub 2012 Oct 29. Am Heart J. 2012. PMID: 23194489 Clinical Trial.
Sudden Death After Hospitalization for Heart Failure With Reduced Ejection Fraction (from the EVEREST Trial).
Vaduganathan M, Patel RB, Mentz RJ, Subacius H, Chatterjee NA, Greene SJ, Ambrosy AP, Maggioni AP, Udelson JE, Swedberg K, Konstam MA, O'Connor CM, Butler J, Gheorghiade M, Zannad F. Vaduganathan M, et al. Among authors: konstam ma. Am J Cardiol. 2018 Jul 15;122(2):255-260. doi: 10.1016/j.amjcard.2018.03.362. Epub 2018 Apr 11. Am J Cardiol. 2018. PMID: 29731121 Free PMC article. Clinical Trial.
A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial.
Gheorghiade M, Pang PS, Ambrosy AP, Lan G, Schmidt P, Filippatos G, Konstam M, Swedberg K, Cook T, Traver B, Maggioni A, Burnett J, Grinfeld L, Udelson J, Zannad F. Gheorghiade M, et al. Heart Fail Rev. 2012 May;17(3):485-509. doi: 10.1007/s10741-011-9280-0. Heart Fail Rev. 2012. PMID: 21932146
Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.
Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Konstam MA, et al. JAMA. 2007 Mar 28;297(12):1319-31. doi: 10.1001/jama.297.12.1319. Epub 2007 Mar 25. JAMA. 2007. PMID: 17384437 Clinical Trial.
355 results